Klinger, D.; Hill, B.L.; Barda, N.; Halperin, E.; Gofrit, O.N.; Greenblatt, C.L.; Rappoport, N.; Linial, M.; Bercovier, H.
Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease. Vaccines 2021, 9, 491.
https://doi.org/10.3390/vaccines9050491
AMA Style
Klinger D, Hill BL, Barda N, Halperin E, Gofrit ON, Greenblatt CL, Rappoport N, Linial M, Bercovier H.
Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease. Vaccines. 2021; 9(5):491.
https://doi.org/10.3390/vaccines9050491
Chicago/Turabian Style
Klinger, Danielle, Brian L. Hill, Noam Barda, Eran Halperin, Ofer N. Gofrit, Charles L. Greenblatt, Nadav Rappoport, Michal Linial, and Hervé Bercovier.
2021. "Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease" Vaccines 9, no. 5: 491.
https://doi.org/10.3390/vaccines9050491
APA Style
Klinger, D., Hill, B. L., Barda, N., Halperin, E., Gofrit, O. N., Greenblatt, C. L., Rappoport, N., Linial, M., & Bercovier, H.
(2021). Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease. Vaccines, 9(5), 491.
https://doi.org/10.3390/vaccines9050491